Back to Search Start Over

Thrombospondin-1 overexpression stimulates loss of Smad4 and accelerates malignant behavior via TGF-β signal activation in pancreatic ductal adenocarcinoma.

Authors :
Matsumura K
Hayashi H
Uemura N
Ogata Y
Zhao L
Sato H
Shiraishi Y
Kuroki H
Kitamura F
Kaida T
Higashi T
Nakagawa S
Mima K
Imai K
Yamashita YI
Baba H
Source :
Translational oncology [Transl Oncol] 2022 Dec; Vol. 26, pp. 101533. Date of Electronic Publication: 2022 Sep 15.
Publication Year :
2022

Abstract

Introduction: Pancreatic ductal adenocarcinoma (PDAC) is characterized by abundant stroma and cancer-associated fibroblasts (CAFs) provide a favorable tumor microenvironment. Smad4 is known as tumor suppressor in several types of cancers including PDAC, and loss of Smad4 triggers accelerated cell invasiveness and metastatic potential. The thrombospondin-1 (TSP-1) can act as a major activator of latent transforming growth factor-β (TGF-β) in vivo. However, the roles of TSP-1 and the mediator of Smad4 loss and TGF-β signal activation during PDAC progression have not yet been addressed. The aim is to elucidate the biological role of TSP-1 in PDAC progression.<br />Methods and Results: High substrate stiffness stimulated TSP-1 expression in CAFs, and TSP-1 knockdown inhibited cell proliferation with suppressed profibrogenic and activated stroma-related gene expressions in CAFs. Paracrine TSP-1 treatment for PDAC cells promoted cell proliferation and epithelial mesenchymal transition (EMT) with activated TGF-β signals such as phosphorylated Akt and Smad2/3 expressions. Surprisingly, knockdown of DPC4 (Smad4 gene) induced TSP-1 overexpression with TGF-β signal activation in PDAC cells. Interestingly, TSP-1 overexpression also induced downregulation of Smad4 expression and enhanced cell proliferation in vitro and in vivo. Treatment with LSKL peptide, which antagonizes TSP-1-mediated latent TGF-β activation, attenuated cell proliferation, migration and chemoresistance with enhanced apoptosis in PDAC cells.<br />Conclusions: TSP-1 derived from CAFs stimulates loss of Smad4 expression in cancer cells and accelerates malignant behavior by TGF-β signal activation in PDAC. TSP-1 could be a novel therapeutic target, not only for CAFs in stiff stroma, but also for cancer cells in the PDAC microenvironment.<br />Competing Interests: Declaration of Competing Interest No conflicts of interest, financial or otherwise, have been declared by the authors.<br /> (Copyright © 2022. Published by Elsevier Inc.)

Details

Language :
English
ISSN :
1936-5233
Volume :
26
Database :
MEDLINE
Journal :
Translational oncology
Publication Type :
Academic Journal
Accession number :
36115074
Full Text :
https://doi.org/10.1016/j.tranon.2022.101533